Press Release: Available for Immediate Release
The Multiple Myeloma Hub, run by Scientific Education Support (SES) in partnership with the European School of Haematology (ESH), has continued to promote significant developments in the treatment and research of multiple myeloma (MM) throughout Q3 of 2021.
In addition to this activity, the Multiple Myeloma Hub has also welcomed Takeda onto their panel of supporters. This additional financial support helps the Multiple Myeloma Hub drive the hub’s goals of providing the latest evidence-based information for novel therapeutics, expert opinions, strategies for disease management, and international congress coverage.
Speaking about the success of the Multiple Myeloma Hub’s activity, Mia Hill, IME Director at Scientific Education Support, said:
“We are delighted with the progress made by the Multiple Myeloma Hub during 2021. In September, the Multiple Myeloma Hub virtually attended the 18th International Myeloma Workshop (IMW 2021) to identify new diagnostics, therapeutics, and disease management approaches for MM. Topics we focused on included basic, preclinical, and clinical aspects of MM and related plasma cell disorders.
“The Multiple Myeloma Hub was also invited to provide coverage for the 9th annual meeting of the Society of Hematologic Oncology (SOHO2021) in September, giving us the opportunity to keep the hub’s audience up to date on the most popular topics from this congress, which included information about cutting-edge developments and clinical applications, with emphasis on novel biological and therapeutic methods, for patients with MM. Reporting at such a prestigious congress enabled us to share the opinions of experts in the field, covering translational research, new treatments, and diagnostic strategies.
“This was followed by the hub’s huge success in covering the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH 2021) later in September. The most interesting areas of clinical research highlighted in this meeting included the role of modern agents for relapsed/refractory myeloma, bispecific antibodies, antibody–drug conjugates, and updates on chimeric antigen receptor (CAR) T cells.”
Combined, our congress coverage resulted in over 100,000 impressions on social media, highlighting that the Multiple Myeloma Hub is a valued and trusted source of information.
In the next quarter, we will be holding a virtual meeting with the members of our prestigious steering committee, which allows us to determine more robust and valuable scientific content that will be added to the Multiple Myeloma Hub.
We are extremely grateful to all our supporters—Pfizer, Sanofi, AbbVie, Bristol Myers Squibb, Genentech, Roche, Amgen, Oncopeptides, Karyopharm Therapeutics—who have helped us achieve this success throughout 2021, and we are delighted to welcome Takeda to our supporter group.
For more information on the Multiple Myeloma Hub, please visit multiplemyelomahub.com. For media enquiries or to explore collaboration opportunities, please contact firstname.lastname@example.org
NOTES TO EDITOR
About multiple myeloma
Multiple myeloma (MM) is a form of blood cancer that begins with aberrant plasma cells—a type of white blood cell—in the bone marrow. It’s called MM as it frequently affects several bones in the body, including the spine, skull, pelvis, and ribs, preventing the bone marrow from producing enough healthy blood cells while damaging and weakening the affected bones. MM accounts for 15% of all blood malignancies and 2% of all cancers.
About the Multiple Myeloma Hub
The Multiple Myeloma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in MM. Our aim is to enhance knowledge of MM through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.
The Multiple Myeloma Hub enables time-stretched HCPs to easily access impactful information that expedites learning and empowers their treatment decisions. Informed by patients, curated by world leaders, and endorsed by expert societies, the Multiple Myeloma Hub supports HCPs worldwide.
The Multiple Myeloma Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
The Multiple Myeloma Hub was founded in partnership with ESH in 2017.
Multiple Myeloma Hub supporters
Funding for our hubs is made possible through financial support from the pharmaceutical industry. All content is developed by SES in collaboration with an expert steering committee. All content is independent, and the educational supporters are allowed no influence on the content.
- Bristol Myers Squibb
- Karyopharm Therapeutics
If you are interested in becoming a Multiple Myeloma Hub supporter, please contact email@example.com.
About Scientific Education Support (SES)
SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our ‘Know’ education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.
Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology, including the ALL Hub, AML Hub, GvHD Hub, Lymphoma Hub, MDS Hub, and MPN Hub.
About the European School of Haematology (ESH)
The European School of Haematology (ESH) is a not-for-profit institution for the dissemination of information and lifelong learning founded in 1985 to promote and facilitate access to state-of-the-art and cutting-edge knowledge in hematology and related disciplines at the European level. ESH conferences present the latest science and insight into new developments in the fields of basic, clinical, and therapeutic research in hematology.